Prevalence of Fibromyalgia in Israel

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT01203865
First received: September 15, 2010
Last updated: October 10, 2011
Last verified: October 2011
  Purpose

The prevalence of fibromyalgia syndrome in the Israeli population is of importance fro planning resource allocation of medical expenditure as well as for identifying demographic and ethnic differences of this unique population compared with other western samples. In the current study the investigators aim at estimating the prevalence of fibromyalgia in this population. For this purpose a two - stage process will be used. First, a population survey will be conducted by telephone, screening for widespread pain and fatigue in the general population. This survey will use the London Fibromyalgia Epidemiology Study Screening Questionnaire. Second, a sample of patients attending the rheumatology clinic will be surveyed with this tool and will be examined in order to determine the actual proportion of patients fulfilling ACR criteria for fibromyalgia. This will enable us to calculate the positive predictive value of the London Fibromyalgia Epidemiology Study Screening Questionnaire in our population and hence to calculate the prevalence of fibromyalgia in the population.


Condition
Fibromyalgia

Study Type: Observational
Official Title: Prevalence of Fibromyalgia in Israel

Resource links provided by NLM:


Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • Prevalence of fibromyalgia in the Israeli population [ Time Frame: 9 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Demographic data on fibromyalgia patients [ Time Frame: 9 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 1200
Study Start Date: October 2010
Estimated Study Completion Date: March 2012
Estimated Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Telephone survey - general population over age 18 Rheumatology patients - patients attending the rheumatology clinic for any reason

Criteria

Inclusion Criteria:

  • Individuals over 18 who consent to answer the survey questions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01203865

Contacts
Contact: Jacob N Ablin, MD 972-3-6973668 jacobab@tasmc.health.gov.il

Locations
Israel
Tel Aviv SOurasky Medical center Recruiting
Tel Aviv, Israel
Contact: Jacob N Ablin, MD    972-3-6973668    jacobab@tasmc.health.gov.il   
Principal Investigator: Jacob N Ablin, MD         
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Pfizer
Investigators
Principal Investigator: Jacob N Ablin, MD Tel-Aviv Sourasky Medical Center
  More Information

Publications:
Responsible Party: Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier: NCT01203865     History of Changes
Other Study ID Numbers: 0303-10-TLV, WS573984
Study First Received: September 15, 2010
Last Updated: October 10, 2011
Health Authority: Israel: Ministry of Health

Keywords provided by Tel-Aviv Sourasky Medical Center:
Fibromyalgia
Fatigue

Additional relevant MeSH terms:
Fibromyalgia
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on August 19, 2014